CI

At a glance

ClinicalIndex Comparison Record
Phase 1Completed· 41 enrolled
Drug / intervention
MLN0264drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01577758
NCT01577758Phase 1Completed
CompareCT.gov

An Open-Label, Dose Escalation, Phase 1, First-in-Human Study of MLN0264 in Adult Patients With Advanced Gastrointestinal Malignancies Expressing Guanylyl Cyclase C

Millennium Pharmaceuticals, Inc.·interventional·Posted Apr 16, 2012·Updated Sep 7, 2016

In Brief

A Phase 1 clinical trial evaluating MLN0264 for Advanced Gastrointestinal Malignancies. Completed, enrolled 41 participants across 1 site.

Detailed Summary

This is an Open-Label, Multicenter, Dose Escalation, First-in-Human Study of MLN0264 in Adult Patients With Advanced Gastrointestinal Malignancies Expressing Guanylyl Cyclase C.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAdvanced Gastrointestinal Malignancies
CountriesUnited States
Collaborators--

Timeline

Phase 1CompletedFinished
201220132014201520162017201820192020202120222023202420252026
First PostedApr 16, 2012
Enrollment StartJun 1, 2012
Primary CompletionFeb 1, 2014
TodayJul 2, 2026
Enrollment to primary: 1.7 yearsPosted 14.2 years ago

Interventions

MLN0264drug

MLN0264 30-minute infusion on Day 1 of each treatment cycle